Online inquiry

IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10232MR)

This product GTTS-WQ10232MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets RHD gene. The antibody can be applied in prevention of feto-maternal allo-immunization in RhD- women research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001127691.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6007
UniProt ID Q02161
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ10232MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13492MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PRTX-100
GTTS-WQ7342MR IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA FPA-150
GTTS-WQ13713MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RC48
GTTS-WQ807MR IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-085
GTTS-WQ7709MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA GEXMab73
GTTS-WQ8344MR IVTScrip™ mRNA-Anti-MUC1, hPAM4(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA hPAM4
GTTS-WQ10059MR IVTScrip™ mRNA-Anti-FN1, L19-IL-2(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA L19-IL-2
GTTS-WQ14701MR IVTScrip™ mRNA-Anti-SELP, SEG101(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SEG101
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW